Inozyme Pharma, Inc.
321 Summer Street
Suite 400
Boston, Massachusetts 02210
July 21, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Inozyme Pharma, Inc. |
Registration Statement on Form S-1
File No. 333-239648
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Inozyme Pharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-239648), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on July 23, 2020, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Brian A. Johnson of Wilmer Cutler Pickering Hale and Dorr LLP at (212) 937-7206.
[Remainder of Page Intentionally Left Blank]
| Very truly yours, | ||
| INOZYME PHARMA, INC. | ||
| By: |
/s/ Axel Bolte | |
| Name: Axel Bolte | ||
| Title: President and Chief Executive Officer | ||
Signature Page to Acceleration Request